13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurological Disorders
Neurological disorders cover a wide spectrum of diseases affecting the central and peripheral nervous systems, ranging from cognitive impairments to movement disorders and pain syndromes. Conditions such as stroke, traumatic brain injuries, and chronic pain are major contributors to disability worldwide. Research in this field is focused on understanding the complex mechanisms that lead to neuronal damage, including inflammation, oxidative stress, and disruptions in synaptic function. Cutting-edge treatments, including stem cell therapy, gene therapy, and neurostimulation, are being explored to promote recovery and restore lost function. Furthermore, precision medicine is transforming the management of neurological disorders by tailoring therapies based on individual genetic and environmental profiles, offering hope for more effective interventions and better patient outcomes.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States